New Crown Outbreak: 24.33 million! FDA grants Abbott COVID-19 antigen test card emergency use authorization: $5, 15 minutes out!

At present, the outbreak of neo-crown pneumonia is still spreading rapidly around the world.
according to Baidu's Real-Time Big Data Report on the Outbreak of New Coronavirus Pneumonia, as of 15 pm on August 26, 2020, there were more than 24.33 million confirmed cases and more than 829,000 deaths worldwide.
, more than 6 million cases and 183,000 deaths have been confirmed in the United States.
to quickly identify people infected with COVID-19 is critical in outbreak prevention and control.
, Abbott announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to binaxNOW COVID-19 Ag Card, the company's COVID-19 rapid antigen test card.
test card allows qualitative testing of new coronavirus (SARS-CoV-2) nuclear crust protein antigens from nasal swabs from suspected COVID-19 patients.
test card uses Abbott's proven lateral flow technology, requiring no instrumentation and only 15 minutes to produce results.
in data submitted to the FDA, a clinical study conducted by Abbott and several leading U.S. research universities showed that among those infected with COVID-19 suspected by health care providers, binaxNOW COVID-19 Ag Card tested 97.1 percent sensitivity (positive compliance) and 98.5 percent specificity (negative compliance) within seven days of the onset of symptoms.
test card, which costs $5, is highly portable (about the size of a credit card) and affordable.
Because no equipment is needed, this test card will be an important tool for managing risk during the COVID-19 pandemic and can serve as a first line of defense to quickly identify and isolate infected people so they don't spread the disease to others.
will also launch a complementary mobile app (app) NAVICA for iPhone and Android devices, the first of its kind and will be available free of charge.
In crowded areas, when asked by organizations such as workplaces and schools, the app will allow people with negative test results, display a temporary digital health pass, display BinaxNOW test results to organization personnel, and update the pass and the date of the test results each time they pass a medical service provider.
organizations will be able to view and verify the information displayed on mobile devices, combining hand washing, social distance, enhanced cleaning and wearing masks to facilitate access to facilities.
plans to distribute tens of millions of test cards in September, reaching 50 million a month by early October.
has invested hundreds of millions of dollars in two new U.S. plants to mass-produce BinaxNOW since April.
robert B. Ford, president and chief executive of Abbott, said: "We have specially designed the BinaxNOW test and NAVIA applications to provide a comprehensive test solution to help Americans have more confidence in their health and lives.
BinaxNOW and NAVICA applications provide us with a reasonably priced, easy-to-use, scalable test, and a complementary digital health tool that helps us to be more normal in our daily lives.
, Chairman of Molecular Virology and Microbiology at Baylor College of Medicine, said: "The large-scale launch of this test card and application will enable tens of millions of people to obtain fast and reliable detection.
laboratory-based tests, you can get excellent sensitivity, but it may take days or more to get results.
with fast antigen testing, you'll get results right away, allowing infectious people to leave the streets and into quarantine so they don't spread the virus.
"